* Abcellera Biologics Inc ABCL.OQ reported a quarterly
adjusted
loss of 2 cents per share for the quarter ended in June. The
mean expectation of seven analysts for the quarter was for a
loss of 2 cents per share.
* Revenue rose 66.1% to $45.92 million from a year ago;
analysts
expected $53.59 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
a
loss of 2 cents.
* The mean earnings estimate of analysts had fallen by
about 133.4% in the last three months.
* In the last 30 days two analysts negatively revised
earnings
estimates
* Abcellera Biologics Inc shares had risen by 10.4% this
quarter and lost 17.8% so far this year.
* The company reported a quarterly loss of $6.79 million.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $32.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data August 10
at 03:47 a.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2022 -0.02 -0.02 Met
Mar. 31 2022 0.38 0.54 Beat
Dec. 31 2021 0.19 0.19 Met
Sep. 30 2021 -0.05 -0.08 Missed